Articles published by Pluristyx, Inc.

CORRECTION: Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery

December 02, 2025

From Pluristyx, Inc.

Via GlobeNewswire

Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery

December 02, 2025

From Pluristyx, Inc.

Via GlobeNewswire

Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies

November 17, 2025

From Pluristyx, Inc.

Via GlobeNewswire

Pluristyx Executes Key Commercial Clinical Use Licenses for iPSC Portfolio, Enabling Novel Therapies for Regenerative Medicine and Neurological Disease Therapeutics

November 05, 2025

From Pluristyx, Inc.

Via GlobeNewswire

Pluristyx and Solesis Announce Strategic Collaboration to Advance Organoid and Cell Therapy Solutions

September 24, 2025

From Pluristyx, Inc.

Via GlobeNewswire

Stem Genomics Announces Partnership with Pluristyx, Leading One-Stop-Shop Solution Provider for High-Quality Cell-Based Therapies

July 18, 2023

From Pluristyx, Inc.

Via Business Wire

Pluristyx and the Advanced Regenerative Manufacturing Institute to Commercialize Clinical-Grade Stem Cells

July 11, 2023

From Pluristyx, Inc.

Via Business Wire

Pluristyx and Accelerated Biosciences Announce Availability of Clinical-Grade Immune-Privileged Human Trophoblast Stem Cells (hTSCs)

April 28, 2022

From Pluristyx, Inc.

Via Business Wire

Pluristyx, panCELLa, and Implant Therapeutics Announce a Strategic Alliance to Manufacture and Distribute Genetically Modified, Clinical-grade Human-induced Pluripotent Stem Cells

January 20, 2022

From Pluristyx, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.